After decades of unfulfilled potential, the commercial reality of gene therapies is rapidly taking shape. This is most evident perhaps in the blood disorders space, being home to a number of the leading candidates under the gene therapy umbrella and most likely the indication we will see the fields next approval in.

In light of this, more gene therapy drug developers are establishing a presence in the blood disease space. These therapies cannot be pioneered without the important services that top solution providers offer - from high-quality diagnostics and coagulation services to ensuring drug developers stand out from the crowd, to exceptional clinical trials run by experts in blood disease.

Having conducted extensive research with Gene Therapy BioPharma we are repeatedly being told that there is a major bottleneck in the blood disorders space in terms of high quality, efficient and effective service providers with whom they can work.

In our first “in-person” meeting within this field since 2019 we are set to unite 100+ clinical, translational, safety and commercial industry experts from the fields leading companies in Boston in March 2022. From extensive research with these organisations, we are aware that they are all actively seeking to collaborate with organizations that can help them solve their drug development challenges.

If you are a contract service provider with expertise in the gene therapy space who can meet these exploding markets’ demands, then The Gene Therapy for Blood Disorders Summit will provide a platform for you to showcase your solutions to a niche audience of experts from the leading gene therapy developers.

We have a limited number of partnership opportunities available, including speaking positions across our agenda.